Insider Selling: Enfusion, Inc. (NYSE:ENFN) Insider Sells 18,241 Shares of Stock

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total value of $147,934.51. Following the transaction, the insider now owns 198,913 shares of the company’s stock, valued at approximately $1,613,184.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bronwen Bastone also recently made the following trade(s):

• On Tuesday, June 18th, Bronwen Bastone sold 10,539 shares of Enfusion stock. The stock was sold at an average price of $8.17, for a total value of $86,103.63.

Enfusion Trading Up 0.5 %

Shares of ENFN stock opened at $8.40 on Thursday. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.56. The stock has a market capitalization of $1.08 billion, a P/E ratio of 280.09, a P/E/G ratio of 1.94 and a beta of 0.96. The firm’s 50 day moving average is $9.10 and its 200 day moving average is $9.07.

Enfusion (NYSE:ENFN) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The firm had revenue of $48.05 million during the quarter, compared to analysts’ expectations of $47.67 million. Enfusion had a return on equity of 6.60% and a net margin of 1.40%. During the same quarter last year, the business earned $0.04 earnings per share. As a group, equities analysts predict that Enfusion, Inc. will post 0.09 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on ENFN shares. The Goldman Sachs Group downgraded shares of Enfusion from a “neutral” rating to a “sell” rating and cut their price objective for the company from $9.00 to $8.00 in a research report on Wednesday, February 28th. Bank of America boosted their price objective on shares of Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a report on Wednesday, March 13th. Finally, Morgan Stanley began coverage on Enfusion in a research note on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target for the company. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Enfusion has an average rating of “Hold” and a consensus price target of $9.33.

Institutional Investors Weigh In On Enfusion

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Enfusion by 17.2% during the third quarter. Vanguard Group Inc. now owns 3,487,815 shares of the company’s stock valued at $31,286,000 after buying an additional 512,479 shares during the period. Scalar Gauge Management LLC bought a new position in Enfusion in the 4th quarter worth $1,993,000. Brown Capital Management LLC grew its holdings in Enfusion by 6.5% during the fourth quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company’s stock valued at $114,631,000 after purchasing an additional 724,502 shares during the period. Hudson Bay Capital Management LP increased its position in Enfusion by 29.7% in the third quarter. Hudson Bay Capital Management LP now owns 460,084 shares of the company’s stock worth $4,127,000 after buying an additional 105,236 shares in the last quarter. Finally, Azora Capital LP bought a new position in shares of Enfusion in the fourth quarter worth about $134,000. 81.05% of the stock is currently owned by institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.